FBXW9

Across TCGA pan-cancer cohorts, FBXW9 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FBXW9 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FBXW9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXW9 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, KIRP, and LUSC are the cancer types where FBXW9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
KIRP	DFS	Median	All	0.316	0.863	<.001	21	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	20	view →
LUAD	OS	Median	All	0.079	0.788	<.001	18	view →
SKCM	DFS	Median	II,III,IV	0.769	0.202	.004	14	view →
BLCA	OS	Median	IV	0.082	0.590	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BRCA	DFS	Median	All	0.642	0.949	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FBXW9–ACC (DFS)

Open the ACC breakdown →